KALA BIO, Inc.
KALAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 30, 2025 | Mizuho Securities | $1.50(-17%) | $1.81 | TheFly | |
| Sep 17, 2025 | H.C. Wainwright | $35.00(+100%) | $17.47 | TheFly | |
| Aug 7, 2024 | H.C. Wainwright | Yi Chen | $15.00(+384%) | $3.10 | TheFly |
| May 17, 2024 | H.C. Wainwright | Yi Chen | $18.00(+454%) | $3.25 | TheFly |
| Apr 3, 2024 | H.C. Wainwright | Yi Chen | $21.00(+425%) | $4.00 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Mizuho | downgrade | Outperform →Neutral | Sep 30, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Sep 29, 2025 |
| H.C. Wainwright | downgrade | Buy →Neutral | Sep 29, 2025 |
| Ladenburg Thalmann | downgrade | Buy →Neutral | Sep 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 17, 2025 |
| Oppenheimer | maintain | Outperform | Sep 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 23, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| Oppenheimer | maintain | Outperform | Aug 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2024 |
| Oppenheimer | maintain | Outperform | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 1, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 12, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 17, 2022 |
| HC Wainwright & Co. | maintain | Buy | Mar 30, 2022 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 19, 2026 | $-21.32 | $-6.00 | — | $25.0M |
| May 15, 2026 | $-0.14 | $-8.50 | — | — |
| Apr 15, 2026 | $0.08 | $-16.00 | — | — |
| Nov 19, 2025 | $-1.07 | $-50.50 | — | — |
| Aug 8, 2025 | $-85.50 | $-91.00 | — | — |
| May 14, 2025 | $-70.50 | $-101.50 | — | — |
| Mar 31, 2025 | $-87.00 | $-114.00 | — | — |
| Nov 12, 2024 | $-96.50 | $-121.50 | — | — |
News
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 1,358,824 shares, a growth of 205.1% from the September 15th total of 445,421 shares. Approximately 7.2% of the company's stock are short sold. Based on an
KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) shares fell 0.9% during mid-day trading on Friday. The stock traded as low as $0.2860 and last traded at $0.2940. Approximately 285,090 shares traded hands during trading, a decline of 92% from the average daily volume of 3,782,051 shares. The stock had previously closed at $0.2966. Wall
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive Proposed purchase price of approximately $15 million, payable in cash a…
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel
Shares of KALA BIO, Inc. (NASDAQ: KALA - Get Free Report) have received a consensus rating of "Reduce" from the five ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 1
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for opht…